首页> British journal of haematology> Pembrolizumab in relapsed or refractory Richter syndrome.

Pembrolizumab in relapsed or refractory Richter syndrome.

导出 OA

翻译打印收藏纠错

第一作者： Philippe,Armand

第一单位： Dana-Farber Cancer Institute, Boston, MA, USA.

作者： Philippe,Armand ^[1] ; Niels,Murawski ^[2] ; Daniel,Molin ^[3] ; Jasmine,Zain ^[4] ; Barbara,Eichhorst ^[5] ; Zafer,Gulbas ^[6] ; Eliza A,Hawkes ^[7] ; John M,Pagel ^[8] ; Tycel,Phillips ^[9] ; Vincent,Ribrag ^[10] ; Jakub,Svoboda ^[11] ; Anastasios,Stathis ^[12] ; Arkendu,Chatterjee ^[13] ; Robert,Orlowski ^[13] ; Patricia,Marinello ^[13] ; Beth,Christian ^[14]

作者单位： Dana-Farber Cancer Institute, Boston, MA, USA. ^[1] Universitäts-klinikum des Saarlandes Innere Medizin I, Homburg, Germany. ^[2] Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. ^[3] City of Hope, Duarte, CA, USA. ^[4] University of Cologne, Cologne, Germany. ^[5] Anadolu Medical Center, Istanbul, Turkey. ^[6] Olivia Newton-John Cancer Research Institute, Austin Health, Victoria, Australia. ^[7] Swedish Center for Blood Disorders and Stem Cell Transplants, Swedish Cancer Institute, Seattle, WA, USA. ^[8] Rogel Cancer Center, Ann Arbor, MI, USA. ^[9] Institut Gustave Roussy, Villejuif, France. ^[10] Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA, USA. ^[11] Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. ^[12] Merck & Co., Inc, Kenilworth, NJ, USA. ^[13] The James Cancer Hospital and Solove Research Institute, Ohio State University, Columbus, OH, USA. ^[14]

关键词 PD-1 Richter syndrome chronic lymphocytic leukaemia immunotherapy pembrolizumab

医学主题词女(雌)性(Female);人类(Humans);白血病, 淋巴细胞, 慢性, B细胞(Leukemia, Lymphocytic, Chronic, B-Cell);男(雄)性(Male);肿瘤复发, 局部(Neoplasm Recurrence, Local)

DOI 10.1111/bjh.16762

PMID 32544980

发布时间 2021-03-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交